EGFR and metastatic colorectal cancer: For example, patients with metastatic colorectal cancer harboring mutations in exon 2 of K-ras did not benefit from anti-epidermal growth factor receptor (EGFR) therapy [11], only those patients with wild-type ras genes could benefit from such treatment [12].